Pulmonary Fibrosis
Pulmonary Fibrosis
Search
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
Health Canada approves OFEV® (nintedanib), the first and only therapy in Canada to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated ILD
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study
INSPIRED
Read more about INSPIRED, aimed at expanding a hospital-to-home program to better support people living with chronic obstructive pulmonary disease (COPD).
Lung Diseases
Lung Diseases
Pommeraie collaborative COPD strategy
La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Heart Diseases
Heart Diseases
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development